For millions of people living with COPD, quitting smoking remains the single most impactful intervention available — yet a striking proportion of clinical encounters pass without the topic being raised. A feasibility study testing a point-of-care visual tool offers a practical, low-cost mechanism for closing that gap, with implications for how behavioral nudges can be embedded directly into clinical workflows.
Researchers at St. Michael's Hospital, University of Toronto, developed a personalized infographic generated through pulmonary function laboratory software and delivered to current smokers with COPD at the time of spirometry testing. The graphic depicted individualized projections of future lung function decline — with and without smoking cessation — alongside corresponding clinical consequences. Patients were instructed to bring the infographic to their consulting provider. The study enrolled 87 patients during a usual-care baseline year and 104 during the infographic intervention year, tracking two co-primary behavioral outcomes via electronic chart review: the proportion of visits documenting smoking cessation counseling and the proportion in which pharmacotherapy was prescribed or recommended.
The broader significance here lies less in the size of the trial and more in its mechanistic logic. Point-of-care risk visualization has shown promise across cardiovascular and diabetes prevention contexts, but its application to COPD-specific lung function trajectories is less developed. By anchoring the conversation to individualized, quantified projections rather than generic warnings, the tool transforms an abstract risk — years of future decline — into a legible, patient-specific narrative. This approach aligns with established behavior-change theory suggesting that perceived personal susceptibility drives engagement more effectively than population-level statistics. As a single-center feasibility study, causal inference is limited, and the absence of randomization means confounding by secular trends in clinical practice cannot be excluded. Longer-term outcomes such as actual cessation rates, quit attempts, or lung function trajectories were not assessed. Nonetheless, the scalability of embedding such tools within existing PFL software infrastructure makes this an incrementally meaningful proof-of-concept worth replicating in larger, controlled designs.